Australian Doctor Australian Doctor 30th June 2017 | Page 9

Safety never gets old
1
51% of Australian T2DM patients are ≥65 years of age
2
For these potentially more complex patients,
safety and tolerability are of increased importance
when optimising individualised care 3,4
JANUVIA has a safety and efficacy profile that
helps simplify the management of your elderly
patients with T2DM: 5-8
No increased risk of hypoglycaemia ^
or fracture vs. placebo 6
Can be used at all stages of renal impairment
(dose according to creatinine clearance) 7
Effective HbA 1c reductions 6,7
when used as monotherapy or in combination
with metformin or pioglitazone 7
^
7
Hypothetical patient.
Before prescribing, please review the Approved Product Information. Product Information is available at www.msdinfo.com.au/januviapi.
PBS Information: Dual therapy: Authority required (STREAMLIINED): 6346. Triple therapy: Authority required (STREAMLIINED): 6366. Insulin add-on therapy: Authority required
(STREAMLINED): 6376. Refer to PBS Schedule for full authority information. Initial add-on therapies are not listed on the PBS. Monotherapy is not listed on the PBS.
JANUVIA Minimum Product Information (PI) Indications: To improve glycaemic control in patients ≥ 18 years old with Type 2 Diabetes Mellitus. Either as monotherapy (when metformin cannot be used and when dietary and exercise measures have failed), or as dual
combination therapy with metformin or with a sulfonylurea, or with a thiazolidinedione where its use is considered appropriate, or as triple combination therapy with metformin and a sulfonylurea, or as add-on to insulin (with or without metformin). Contraindications:
Hypersensitivity to any component. Precautions: Not for Type 1 Diabetes Mellitus or diabetic ketoacidosis. Acute pancreatitis (discontinue treatment), renal insufficiency, hypoglycaemia in combination with a sulfonylurea or with insulin, hypersensitivity, bullous
pemphigoid (discontinue treatment). Pregnancy (Cat B3), lactation, children. Interactions: No clinically significant interactions observed with sitagliptin and metformin, glibenclamide, simvastatin, rosiglitazone, warfarin, oral contraceptives, digoxin or cyclosporine (see
full PI). Adverse reactions: URTI, headache, hypoglycaemia, nasopharyngitis. Postmarketing Experience: Hypersensitivity reactions, Acute pancreatitis, Worsening renal function (including acute failure), constipation, vomiting, headache, arthralgia, myalgia, pain in
extremity, back pain (see full PI). Dosage: 100 mg once daily with or without food. Adjust dose for moderate/severe renal insufficiency (see full PI). Consider reduced dose of sulfonylurea/insulin when used in combination. Based on PI amended: JANUVIA: 06 April 2017.
References: 1. AIHW: Webbie K & O’Brien K 2006. Use of medicines by Australians with diabetes. Bulletin no. 47. AIHW cat. no. AUS 82. Canberra: AIHW. 2. Australian Bureau of Statistics. National Health Survey: First Results, 2014-15 (4364.0.55.001). Table 3:
Long-term health conditions – Australia. Issued December 2015. 3. The Royal Australian College of General Practitioners. General practice management of type 2 diabetes: 2016–18. East Melbourne, Vic: RACGP, 2016. 4. Australian Diabetes Society. A new blood
glucose management algorithm for type 2 diabetes: A position statement of the Australian Diabetes Society. Updated December 2016. diabetessociety.com.au/position-statements.asp. Accessed February 2017. 5. Round EM et al. Drugs Aging 2014; 31(3): 203–14.
6. Barzilai N et al. Curr Med Res Opin 2011; 27(5): 1049–58. 7. JANUVIA Approved Product Information, April 2017. 8. Bethel MA et al. Diabetes Care 2017 Jan 5. doi: 10.2337/dc16-1135.
Copyright © 2017 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, New Jersey, U.S.A. All rights reserved. Merck Sharp & Dohme (Australia) Pty Limited. Level 1 – Building A, 26 Talavera Road,
Macquarie Park NSW 2113. DIAB-1212163-0001. First issued April 2017. MSDDIA1316.